Clinical trials: Tumor Patients
Non-Small Cell Lung Cancer (NSCLC)
A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804
This study will enroll patients who are planned to undergo surgical removal of their tumor. The goal of the study is to evaluate the changes that occur in the tumor after brief (about 8 days) exposure to the study drug.
- Trial name
- NCT00971191
- Testing
- PF-00299804
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pfizer
HPV-Related Cervical Carcinoma, HPV-Related Malignancy
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
This is a multi-center study in patients with recurrent or metastatic HPV16-positive, PD-L1 positive cervical cancer who has progressed during or after treatment with the first-line standard of care (pembrolizumab with…
- Conditions
- HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
- Trial name
- NCT06099418
- Testing
- VB10.16, Atezolizumab Injection [Tecentriq]
- Sponsor
- Nykode Therapeutics ASA
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Primary: The primary objective of this study under the original protocol was to provide neuromuscular specialists and neurologists access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus…
- Conditions
- Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
- Trial name
- EAP-001 (NCT02189720)
- Testing
- Amifampridine Phosphate
- Where
- United States
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
- Trial name
- TARGET-D 202 (NCT07659782)
- Testing
- VS-7375
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 105 people
- Sponsor
- Verastem, Inc.
Pain; Cancer
An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics
The purpose of this study is to evaluate the efficacy and safety of Transdermal Therapeutic System (TTS)-fentanyl D-Trans (transdermal patch containing a drug that is put on the skin so the drug will enter the body through the…
- Trial name
- NCT01060124
- Testing
- Fentanyl D-trans
- Volunteers
- 103 people
- Sponsor
- Janssen Korea, Ltd., Korea
Melanoma
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
An observational study of melanoma participants who are eligible for and who have initiated treatment with adjuvant nivolumab as part of routine clinical practice.
- Trial name
- NCT03771859
- Where
- 14 sites in Belgium, Luxembourg
- Volunteers
- 152 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms
Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Primary: Maximum tolerated dose (MTD) Secondary: Determination of the pharmacokinetic profile of BI 2536. Assessment of safety and efficacy.
- Trial name
- NCT02211859
- Testing
- BI 2536
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer, Pancreatic Cancer
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite
- Trial name
- PROACC-1 (NCT05546476)
- Testing
- ponsegromab
- Where
- 78 sites in United States, Australia and 9 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Breakthrough Pain, Cancer
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks.
- Trial name
- GENISIS (NCT00994760)
- Testing
- Instanyl (Intranasal Fentanyl)
- Where
- 168 sites in Germany
- Volunteers
- 131 people
- Sponsor
- Takeda
Advanced Solid Tumor
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single…
- Trial name
- NCT04735978
- Testing
- RP3, Nivolumab
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 123 people
- Sponsor
- Replimune, Inc.
Metastatic Castration-resistant Prostate Cancer
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled.
- Trial name
- PRESERVE-006 (NCT05682443)
- Testing
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Where
- 23 sites in United States
- Volunteers
- 148 people
- Sponsor
- OncoC4, Inc.
Neoplasms
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
This is the first study where BAY1125976 is given to humans. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated…
- Trial name
- NCT01915576
- Testing
- BAY1125976
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 79 people
- Sponsor
- Bayer
Advanced Solid Tumors
Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial, which aims to observe and evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of HRS2398…
- Trial name
- NCT06439589
- Testing
- HRS2398, Adebrelimab
- Where
- 2 sites in China
- Volunteers
- 88 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumor
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors
This is the first in human study of BL0020, and the primary objective is to evaluate the safety and tolerability, and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of BL0020 as a single agent in…
- Trial name
- NCT05886868
- Testing
- BL0020
- Where
- 4 sites in Australia, China
- Volunteers
- 66 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Solid Tumor, Adult, Relapsed Cancer
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of…
- Conditions
- Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05662397
- Testing
- HST-1011, Cemiplimab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 77 people
- Sponsor
- HotSpot Therapeutics, Inc
Prostate Cancer
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when…
- Trial name
- NCT00035997
- Testing
- Zometa
- Where
- 56 sites in United States
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
This is a single center, open-label, nonrandomized, phase 1b, dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
- Trial name
- NCT03780010
- Testing
- TRC105
- Volunteers
- 15 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Triple Negative Breast Neoplasms
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
- Trial name
- CAPItello-290 (NCT03997123)
- Testing
- Capivasertib, Paclitaxel
- Where
- 260 sites in United States, Argentina and 28 more
- Volunteers
- 923 people
- Sponsor
- AstraZeneca
Advanced Liver Cancer
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma
- Trial name
- NCT05698459
- Testing
- OH2 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Advanced Cancer, Cachexia
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
- Trial name
- NCT06736275
- Testing
- SXRN
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.